2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.
Aug 24, 2026DOI: 10.1093/cid/ciaf680Journal ArticleCID
Written by: Amy Hirsch ShumakerAdarsh BhimrajRoger BedimoVincent Chi-Chung ChengKara W ChewEric S DaarDavid V GliddenRobert W ShaferPhyllis C TienLindsey R BadenKelly CawcuttKathleen ChiotosAmy L DzierbaErica J HardySteven JohnsonArthur Y KimChristine MacBrayneGreg S MartinNandita NadigMari M NakamuraCarlos R OliveiraJeffrey C PearsonLaura RileyShmuel ShohamPablo TebasZachary WillisJoshua WolfJennifer LovelessRebecca L MorganYngve Falck-YtterRajesh T Gandhi
Find these authors on Roon
AK
Dr. Arthur Kim
HIV/AIDS Medicine · MGH
SS
Dr. Shmuel Shoham
Transplant/Immunocompromised States · Johns Hopkins
Summary
This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.
AK
Dr. Arthur Kim
Infectious Disease · HIV & AIDS MedicineMassachusetts General Hospitalarthurkim